Tabula Rasa HealthCare is recognized for its “innovative solutions that are making an impact on cost, quality, and access in health care.” TRHC develops offerings for the ever-growing segment of the healthcare system that is “at risk,” providing tools and services to better manage risk.
Philadelphia, PA, June 05, 2015 –(PR.com
)– Tabula Rasa Healthcare, Inc. is the winner of the PACT 2015 Enterprise Awards for Healthcare Innovator Company of the Year. The announcement was made at a gala event held May 14 in Philadelphia, PA. A first-time Enterprise Award category, Healthcare Innovator recognizes companies that are providing “an innovative solution that has the potential to make a large and positive impact on cost, quality, and/or access in health care.”The Health Care Innovator Award citation, sponsored by Independence Blue Cross, described the winner: “Tabula Rasa HealthCare (TRHC) is a family of companies devoted to leveraging technology to improve healthcare. TRHC develops offerings for the ever-growing segment of the healthcare system that is ‘at risk.’ As providers grapple with new reimbursement models, as managed and accountable care organizations continue to expand, and as new partnerships emerge between payers and providers, they seek new ways to better manage their risk. TRHC offers those tools and services.”TRHC Chairman and CEO, Calvin H. Knowlton, BSPharm, MDiv, PhD thanked Dean E. Miller, PACT President and CEO, the judges and the TRHC team members for this welcomed award. “We are honored to have been selected for this prestigious award for healthcare innovation,” said Knowlton. “The work we are doing in medication informatics, personalized medication management, and compliance/assurance is exciting and, we believe, game changing.”Partnering with healthcare organizations in the vanguard of coordinated care, TRHC results include enhanced medication-related outcomes and greater operational efficiency.The Enterprise Awards are the Greater Philadelphia Region’s most prestigious business honors for technology and life science companies, leaders and entrepreneurs.About Tabula Rasa Healthcare
Tabula Rasa HealthCare (TRHC), through its companies CareKinesis™, CareVentions™, Capstone Performance Systems™, and Medliance™, offers medication informatics, personalized medication management, and compliance/assurance to payers and providers to mitigate medication risk, lower costs and improve outcomes. TRHC is the market leader in PACE (Program of All-Inclusive Care for the Elderly) medication safety solutions, and provides pharmacy cost management technology to skilled nursing facilities throughout the country.
2015 Enterprise Awards Honoree and Winners
Tabula Rasa Healthcare
Sponsor: Independence Blue Cross
Life Sciences CEO
Jeffrey D. Marrazzo, Spark Therapeutic
Sponsor: EY and Drinker Biddle & Reath
Life Sciences Emerging
Excellis Health Solutions
Life Sciences Startup
Sponsor: University City Science Center and University of Pennsylvania
Sponsor: Comcast Business
Lars Bjork, Qlik
Sponsor: Cozen O’Connor
Sponsor: Ben Franklin Technology Partners and Pepper Hamilton
NewSpring Capital/LLR Partners
Sponsor: Grant Thornton and Franklin Square Capital Partners
CareKinesis announces first quarter 2015 increase in growth. Seven new or expanded Programs for All Inclusive Care of the Elderly sign on with CareKinesis, a Tabula Rasa HealthCare Company.
Moorestown, NJ, April 01, 2015 –(PR.com)– CareKinesis CEO Calvin H. Knowlton, BscPharm, MDiv, PhD, reported today the Company has contracted with seven (7) new or expansion client Programs of All-Inclusive Care for the Elderly (PACE) in 2015. Program locations include: LIFE Armstrong, Kittaning, Pennsylvania and an expansion location of VieCare/Lutheran Senior LIFE, Aliquippa; Brandman Centers for Senior Care, Reseda, California; Franciscan Senior Health and Wellness, Indianapolis, Indiana; InnovaCares for Seniors, Fairfax, Virginia; LIFE PACE, Inc., Tulsa, Oklahoma; Senior CommUnity Care, Lansing, Michigan; and Valir PACE, Oklahoma City, Oklahoma.
Since its start-up in 2011, CareKinesis has grown over 100% year after year, now servicing over 50 PACE centers in 17 States.PACE, in some states known as Living Independence for Elders (LIFE), provides comprehensive, community-based, long-term care services and support to Medicaid and Medicare enrollees. An interdisciplinary team of health professionals provides individuals with coordinated care, including medication management. For most participants, the comprehensive service package enables them to receive care at home rather than in a nursing home.PACE/LIFE organizations nationwide rely on CareKinesis to personalize medication selection, and increase medication adherence, resulting in reduced participant hospitalizations and recidivism. CareKinesis accomplishes this through expert clinical pharmacist support, EireneRx® Medication Risk Mitigation platform, custom adherence medication packaging, and flexible medication access options.
“We are proud and excited to welcome our newest PACE clients to the outcomes-focused services of CareKinesis,” said CEO Knowlton. “Our goal is to consistently reduce medication-related risk while documenting improved economic, clinical, and humanistic outcomes.”
According to client Susie Fishenfeld, RN, MSN, Executive Director, Brandman Centers for Senior Care, Reseda, CA, “Working with our new partner, CareKinesis, I believe our participants’ medication adherence, medication education, and overall health and wellness, will be enhanced.”
CareKinesis partners with health care organizations to provide personalized medication therapy management and pharmacy services for high-,risk populations. The results are enhanced medication-related outcomes and greater operational efficiency. It is the first national PACE-specific pharmacy and the safe choice for PACE organizations. CareKinesis is a Tabula Rasa HealthCare Company.
EOLA, Pa.–(BUSINESS WIRE)–The chief executive officers of Alnylam Pharmaceuticals (NASDAQ: ALNY), Apogee Enterprises (NASDAQ: APOG), Proofpoint, Inc. (NASDAQ: PFPT) and CareKinesis (privately held) have been named as the recipients of the fifteenth annual “E-3 Awards,” presented by Emerald Asset Management at the 22nd Annual Emerald Groundhog Day Investment Forum, held in Philadelphia on February 5, 2015.
Joseph Besecker, President of Emerald Asset Management said, “We created this unique award to recognize leaders who epitomize the qualities that are inherent in the most successful business leaders – qualities that reflect an entrepreneurial spirit and a commitment to excellence,” adding, “The award’s name – E-3 – reflects these criteria: the Emerald Entrepreneurial and Excellence Award.” Joseph Garner, Director of Research for Emerald, said, “These leaders have taken risks and fueled innovation. They have created jobs and built companies. They have bested their competitors and rewarded their employees and shareholders. They are leaders in every sense of the word.”
Through an intensive multi-faceted process, Emerald’s team of research analysts and portfolio managers identified corporate leaders who have demonstrated:
- A creative “outside the box” approach to corporate achievement;
- An entrepreneurial approach that maximizes human initiative;
- A corporate culture that promotes personal and corporate excellence;
- A demonstrated record of accomplishment: creating jobs, stimulating growth, and enhancing shareholder value; and
- An ability to effectively identify and adapt cutting-edge technologies and processes.
The 2015 winners of the E-3 Award are:
Public Company Executive Award:
- Dr. John Maraganore, Chief Executive Officer, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
Public Company Science & Technology Executive Award:
- Gary L. Steele, Chief Executive Officer, Proofpoint, Inc. (NASDAQ: PFPT)
Green Company Executive Award:
- Joseph F. Puishys, President & Chief Executive Officer, Apogee Enterprises, Inc. (NASDAQ: APOG)
Warren “Pete” Musser Private Company Executive Award:
- Dr. Calvin H. Knowlton CEO, Chairman and Founder, CareKinesis, Inc.
Presented by Emerald Asset Management, Groundhog Day Investment Forum sponsors include Pepper Hamilton LLP, Sturdivant & Co., Janney Capital Markets, Trout, Ebersole & Groff LLP, Boenning & Scattergood and Greentree. The first Emerald Investment Forum was held in 1994 and has grown to become the definitive yearly kick-off conference for investors focusing on small- and mid-cap companies.
Founded in 1991, Emerald Asset Management, Inc. is a diversified investment management company that operates through its subsidiaries Emerald Advisers, Inc., Emerald Mutual Fund Advisers Trust, Emerald Separate Account Management, LLC, Emerald Fixed Income Advisers, LLC and Emerald Direct Lending Advisers, LLC. Assets managed by these companies totaled over $3.2 billion as of December 31, 2014. “Driven by Research,” Emerald employs an intense fundamental, research-focused investment philosophy and focuses primarily on growth-oriented equity investing and high-quality disciplined fixed-income investing.
Emerald Asset Management, Inc.
Emerald Advisers, Inc.
Emerald Fixed Income Advisers LLC
Emerald Mutual Fund Advisers Trust
Emerald Separate Account Management LLC
Emerald Direct Lending Advisers LLC
3175 Oregon Pike
Leola, PA 17540
King of Prussia, PA
LAS VEGAS – 29 Apr 2014: IBM (NYSE: IBM) today announced a collaboration with Coriell Life Sciences, a provider of genetic analysis at point of care, and CareKinesis, Inc., a Medication Risk Mitigation® pharmacy services firm, to bring personalized medicine to the elderly based on analyzing and storing genetic data in a secure cloud environment.
Using SoftLayer, an IBM Company, Coriell Life Sciences, in collaboration with IBM and CareKinesis, is launching an initiative with Program for All Inclusive Care of the Elderly (PACE) clients, which cares for more than 5,000 seniors, helping to enhance medication safety by better understanding how high-risk individuals respond to specific medications and drug treatments. Currently, about three out of four older Americans have multiple chronic health conditions. Many of these patients are being treated with drugs that may work at odds with each other – the medication being used for one condition can actually make another condition worse.
By 2030, one in five Americans will be over age 65. As a result, increasing healthcare costs and the healthcare system are just beginning to feel the burden.
“The goal of personalized medicine is to individualize healthcare by using knowledge of patients’ health history, behaviors, environments, and, most recently, individual genetic makeup when making clinical decisions,” explained CareKinesis CEO Calvin H. Knowlton, BSPharm, MDiv, PhD. “This initiative will allow physicians to collaborate with CareKinesis pharmacists to access a patient’s genetic data to better understand what drug treatments are likely to be responded to, thus reducing medication-related problems and hospital visits, while decreasing the individual’s overall healthcare costs.”
Overcoming the Big Data Challenge
Working with genetic data presents massive challenges for both data storage and privacy protection. A whole human genome produces more than three billion points of data for a single individual. To address these issues, Coriell Life Sciences turned to a cloud storage service based on SoftLayer.
In collaboration with IBM, Coriell Life Sciences built a scalable, cloud-based solution that safely and cost-effectively stores data in Coriell Life Sciences’ GeneVault. The GeneVault stores and manages millions of genetic data points. This data is then interpreted and shared with physicians through CareKinesis who layer additional medication management decision factors into a holistic tool for doctors within PACE organizations.
Under the strict privacy controls of the interconnected CareKinesis and Coriell Life Sciences systems, physicians, healthcare providers and medical experts can access a patient’s genomic interpretation via any web connected device. For example, a cardiologist may consider prescribing a popular blood-thinning drug for an elderly man, but may be concerned about the potential for an adverse reaction. The PACE Team decides to conduct a test to assess if the participant will respond to the medication being considered. The test is run by swabbing the inside of the patient’s cheek to collect a tiny amount of genetic material, which goes to Coriell Life Sciences for testing. Results are analyzed and interpreted for their impact on drug response. The resulting report is then transmitted to the doctor giving guidance on whether the patient can safely use the drug. CareKinesis supports the process by making pharmacotherapy recommendations based on these results. The data can be used at any time it is needed in the future for pharmacotherapy prescribing decisions.
“This approach of treating conditions “one at a time” even if the treatments might conflict with one another has been common in medicine, in part because little information exists to guide practitioners in how to consider this problem, weigh alternatives and identify different options. Better understanding of an individual’s genome can lead to a more effective dosage regimen,” said Scott Megill, CEO of Coriell Life Sciences. “Now with the collaboration with IBM and CareKinesis, personalized medicine is presenting many new options to this growing demographic. The combination of cloud and mobile is making a healthcare ecosystem possible with the patient center stage, delivering health services more efficiently.”
For more information on Coriell Life Sciences, visit http://www.coriell.com/
For more information on CareKinesis, visit http://www.carekinesis.com/
For more information on IBM Healthcare, visit www.ibm.com/industries/healthcare/
For more information about cloud offerings from IBM, visit http://www.ibm.com/cloud.
For more information on IBM Impact, visit www.ibm.com/press/ibmimpact2014.
Technology solution provides PACE Programs with real-time connectivityto enhance prescription ordering and delivery processes.
MOORESTOWN, NJ, April 7, 2014- RTZ Associates, a leading provider of cloud-based software to community long-term care organizations and CareKinesis, a medication therapy management and pharmacy services firm, have partnered to develop web-based interoperability between RTZ’s PACECare™ Electronic Health Record and CareKinesis’s EireneRx™ pharmacy application to support Programs of All-Inclusive Care for the Elderly (PACE) organizations. A streamlined workflow for PACE clinicians and enhanced communication between prescribers and CareKinesis pharmacists will aid in selecting the best medication and managing complex medication regimens.
The solution includes the integration of EireneRx e-prescribing platform within the PACECare EHR. When ready to prescribe a medication, users will click on an Rx link and are directed into the medication prescribing tool in EireneRx. Within EireneRx, doctors and nurse practitioners have access to best-of-breed medication risk guidance. They may also directly message a pharmacist for therapy suggestions in real-time. Once the e-prescribing is complete, they are seamlessly ported back to the PACECare.
“Our goal with PACECare has always been to provide as many workflow automation and time-saving features for our users as possible, so we’re really excited about integrating EireneRx with PACECare,” states Michael Zawadski, JD, President of RTZ Associates. “This integration eliminates the need to sign-in to a separate system, eliminates duplicate data entry, reduces the potential for medication errors, and ultimately shortens the amount of time to prescribe and fill medications,” Zawadski continues.
“Improving medication management through technology solutions is a goal of both RTZ and CareKinesis,” added CareKinesis Chairman and CEO, Calvin H. Knowlton, BSPharm, MDiv, PhD. “It makes sense to work together on behalf of our PACE clients to enhance prescription ordering, adherence and results.”
According to Knowlton, “PACE programs are uniquely responsible to manage their patient’s health and are financially accountable. Our goal is to decrease medication-related risk, enhance quality of care and provide improved pharmacotherapy outcomes utilizing leading technology solutions. We partner with organizations that are clinically and economically responsible for persons taking many medications.”
CareKinesis partners with healthcare organizations to provide personalized medication therapy management and pharmacy services for high-risk populations. The results are enhanced medication-related outcomes and greater operational efficiency. The CareKinesis Medication Care Plan Support Center and Medication Adherence Packaging Pharmacy deliver individually customized medicine using unique robotic technology and a proprietary web-based electronic medication management and reporting platform, EireneRx™. It is the first, national PACE-specific pharmacy. CareKinesis is headquartered in Moorestown, NJ. For more information, please visit www.carekinesis.com.
About RTZ Associates:
RTZ Associates, Inc. (RTZ) is the leading provider of cloud-based software solutions to community long-term care organizations. The company serves clients of all types and sizes – from state agencies to community-based centers. By automating workflow and supporting data-driven decision-making, RTZ software solutions reduce operational costs and improve outcomes, fulfilling its motto of, “Systems that work. People who care.” For more information, please visit www.rtzassociates.com.
Michael Zawadski Sara Baughn
RTZ Associates Inc. CareKinesis, Inc.
Moorestown, NJ, February 18, 2014 – CareKinesis, a medication risk management and pharmacy services firm, announced the addition of St. Mary Prescription Pharmacy, San Francisco, CA.
St. Mary Prescription Pharmacy has been servicing the needs of frail elderly PACE (Program for All-Inclusive Care) participants in California for over 30 years. Its focus on participant care and customer service has earned its long-term partnerships. Gary Tom, PharmD, who has been at St. Mary Prescription Pharmacy for over 20 years, purchased the pharmacy practice from the original owner. Dr. Tom is now VP, Client Services and West Coast Operations for CareKinesis. Tom also will continue as Pharmacist-in-Charge at St. Mary Prescription Pharmacy.
“We are delighted to bring in the decades of experience and expertise of Dr. Gary Tom and the St. Mary Prescription Pharmacy Team to CareKinesis. The resources of CareKinesis, including state-of-the-art technology and Medication Risk Mitigation™ systems, and St. Mary Prescription Pharmacy are now available to PACE and other organizations that manage high-risk elderly populations on the West Coast.” said Calvin H. Knowlton, PhD, CEO of CareKinesis.
CareKinesis partners with healthcare organizations to provide personalized medication therapy management and pharmacy services for high-risk populations. The results are enhanced medication-related outcomes and greater operational efficiency. It is the first, national PACE-specific pharmacy. CareKinesis is headquartered in Moorestown, New Jeresey and has three two other locations including San Francisco, California, in Boulder, Colorado, and Charleston, South Carolina. For more information, please visit www.carekinesis.com.
DLS International, Inc.
Traci Hubler, RN, has a passion for serving geriatric clients. As the Director of Quality, she coordinates quality, compliance, performance improvement, and internal and external education initiatives at CareKinesis. She also supports the Marketing/New Business/Client Development and Implementation team as a clinical liaison. read more
MOORESTOWN, NJ, June 10, 2011 – CareKinesis, Inc. Vice Chairman and CFO, Harry G. Hayman, III, was named a finalist for the New Jersey Technology Council’s 2011 CFO Hall of Fame. The award is presented to “a current or former Chief Financial Officer for multiple achievements over an extended period of time, in one company or several, that has elevated him to a level of recognition among community, peers and others involved in the technology arena”. read more
The Medication Management and Personalized Medicine Pacesetter
Rapidly-growing personalized medication selection and customized adherence packaging provider closes growth equity financing
MOORESTOWN, NJ, April 2011 – CareKinesis, Inc. announced it has closed a second round of financing from Originate Ventures and Emerald Stage2 Ventures bringing the total investment by these firms to $3 million. Additional substantial funding also has been provided by the founders and angel investors to fund the growth of the medication management and adherence packaging leader. Proceeds will expand development, equipment purchasing, sales and marketing.
CareKinesis is a new breed medication management company that aims to personalize the medication selection process and customize adherence packaging of medication for high risk populations, such as seniors and behavioral health patients. “We optimize pharmacotherapy outcomes for individuals with complex medication needs,” says Calvin H. Knowlton, BSPharm, MDiv, PhD, CareKinesis Chairman and CEO. “We partner with organizations that are clinically and economically responsible for persons taking many medications.”